J.P. Morgan Keeps Their Sell Rating on GlaxoSmithKline (GSK)
In a report released today, Zain Ebrahim from J.P. Morgan maintained a Sell rating on GlaxoSmithKline, with a price target of £17.00.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Ebrahim is ranked #10728 out of 12068 analysts.
In addition to J.P. Morgan, GlaxoSmithKline also received a Sell from Barclays’s James Gordon CFA in a report issued on April 7. However, today, Jefferies maintained a Buy rating on GlaxoSmithKline (LSE: GSK).
Based on GlaxoSmithKline’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of p8.62 billion and a net profit of p636 million. In comparison, last year the company earned a revenue of p8.12 billion and had a net profit of p414 million
Based on the recent corporate insider activity of 317 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GSK in relation to earlier this year.
Read More on GB:GSK:
Disclaimer & DisclosureReport an Issue
- GSK’s B7-H4 Antibody-Drug Conjugate Shows Strong Early Results in Gynaecological Cancers
- GSK Expands Share Buyback, Lifts Treasury Holdings to 6.36% of Voting Rights
- GSK Executives Reinvest Dividends Into Company Shares Under Reward Plan
- GSK Adds 330,000 Shares to Treasury in Ongoing Buyback Programme
- GSK pulls application for leucovorin calcium, WSJ reports
